Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SURESH G NAIR

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1669423711
CMS profile
166428
Location
ALLENTOWN, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$78.24

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $78.24 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $78.24 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SURESH G NAIR

NPI 1669423711 · CMS profile ID 166428

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

ALLENTOWN, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1669423711?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SURESH G NAIR, NPI 1669423711, CMS profile ID 166428. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669423711?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). SURESH G NAIR, NPI 1669423711, CMS profile ID 166428. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669423711?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
SURESH G NAIR, NPI 1669423711, CMS profile ID 166428, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1669423711?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $78.24 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $78.2402/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016286309 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $125.76 9
PY2020 $69.07 4
PY2021 $61.31 4
PY2022 $80.04 1
PY2023 $78.24 1
PY2024 $149.49 2
PY2025 $295.85 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $194,965.34 40
PY2024 Principal investigator $148,310.84 44
PY2023 Principal investigator $382,804.46 29
PY2022 Principal investigator $135,383.95 27
PY2021 Principal investigator $617,414.43 31
PY2020 Principal investigator $541,006.34 33
PY2019 Principal investigator $398,239.66 27

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

40 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $8,610.75 12/31/2025 Covered Recipient Teaching Hospital
Lehigh Valley
A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma mRCC KEYNOTE No dispute reported 06/30/2026 1232926001
Principal investigator 1 Merck Sharp & Dohme LLC $9,502.40 12/31/2025 Covered Recipient Teaching Hospital
Lehigh Valley
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 Therapy No dispute reported 06/30/2026 1232931712
Principal investigator 1 Merck Sharp & Dohme LLC $3,790.00 12/08/2025 Covered Recipient Teaching Hospital
Lehigh Valley
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 Therapy No dispute reported 06/30/2026 1232931710
Principal investigator 1 Aveo Pharmaceuticals, Inc. $200.95 10/30/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910219
Principal investigator 1 Aveo Pharmaceuticals, Inc. $258.97 10/30/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910221
Principal investigator 1 Aveo Pharmaceuticals, Inc. $258.97 10/30/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910223
Principal investigator 1 Aveo Pharmaceuticals, Inc. $258.97 10/30/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910225
Principal investigator 1 Aveo Pharmaceuticals, Inc. $258.97 10/30/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910227
Principal investigator 1 Aveo Pharmaceuticals, Inc. $258.97 10/30/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910229
Principal investigator 1 Aveo Pharmaceuticals, Inc. $258.97 10/30/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910231
Principal investigator 1 Aveo Pharmaceuticals, Inc. $258.97 10/30/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910233
Principal investigator 1 Aveo Pharmaceuticals, Inc. $120.77 10/30/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910235
Principal investigator 1 Aveo Pharmaceuticals, Inc. $258.97 10/30/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910237
Principal investigator 1 Aveo Pharmaceuticals, Inc. $258.97 10/30/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910393
Principal investigator 1 Aveo Pharmaceuticals, Inc. $258.97 10/30/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910395
Principal investigator 1 Aveo Pharmaceuticals, Inc. $258.97 10/30/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910397
Principal investigator 1 Aveo Pharmaceuticals, Inc. $120.77 10/30/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910399
Principal investigator 1 Aveo Pharmaceuticals, Inc. $320.88 10/30/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910401
Principal investigator 1 Aveo Pharmaceuticals, Inc. $120.77 10/30/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910403
Principal investigator 1 Aveo Pharmaceuticals, Inc. $364.70 10/30/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910405
Principal investigator 1 Aveo Pharmaceuticals, Inc. $120.77 10/30/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910407
Principal investigator 1 Aveo Pharmaceuticals, Inc. $255.22 10/30/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910409
Principal investigator 1 Merck Sharp & Dohme LLC $4,155.52 10/17/2025 Covered Recipient Teaching Hospital
Lehigh Valley
A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma mRCC KEYNOTE No dispute reported 06/30/2026 1232925999
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $84,846.00 10/02/2025 Covered Recipient Teaching Hospital
Lehigh Valley
A Phase 1/1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants with Advanced Malignant Tumors No dispute reported 06/30/2026 1236000800
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,086.94 08/28/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910209
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,589.66 06/30/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910193
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,589.66 06/30/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910195
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,589.66 06/30/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910197
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,589.66 06/30/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910199
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $10,500.00 06/16/2025 Covered Recipient Teaching Hospital
Lehigh Valley
A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma No dispute reported 06/30/2026 1236000796
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,375.97 05/27/2025 Covered Recipient Teaching Hospital
Lehigh Valley
A Phase 1/1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants with Advanced Malignant Tumors No dispute reported 06/30/2026 1236000802
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,086.94 04/28/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910191
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,423.00 03/17/2025 Covered Recipient Teaching Hospital
Lehigh Valley
An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Nave Stage IV or Recurrent Non Small Cell Lung Cancer No dispute reported 06/30/2026 1236000792
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,695.50 03/06/2025 Covered Recipient Teaching Hospital
Lehigh Valley
Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies No dispute reported 06/30/2026 1236000790
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,000.00 02/18/2025 Covered Recipient Teaching Hospital
Lehigh Valley
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for Recurrence No dispute reported 06/30/2026 1236000784
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,086.94 01/27/2025 Non-covered Recipient Entity
Memorial Sloan-Kettering Cancer Center
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910189
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $23,048.24 01/21/2025 Covered Recipient Teaching Hospital
Lehigh Valley
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 1236000786
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,127.00 01/16/2025 Covered Recipient Teaching Hospital
Lehigh Valley
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) No dispute reported 06/30/2026 1236000794
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,893.00 01/15/2025 Covered Recipient Teaching Hospital
Lehigh Valley
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for Recurrence No dispute reported 06/30/2026 1236000788
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,905.00 01/09/2025 Covered Recipient Teaching Hospital
Lehigh Valley
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab andNivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma [RELAtivity-098] No dispute reported 06/30/2026 1236000798